Please use this identifier to cite or link to this item:
Title: Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases.
Austin Authors: Musci, Jason O D ;Cornish, Jack Stephen;Däbritz, Jan
Affiliation: Department of Intensive Care, Austin Health, Heidelberg, Victoria, Australia
School of Medicine, Deakin University, Geelong, VIC, 3220, Australia
Department of Paediatrics, University Children's Hospital Rostock, Ernst-Heydemann-Str. 8, 18057, Rostock, Germany
Issue Date: Jun-2016 2016-03-14
Publication information: Journal of gastroenterology 2016; 51(6): 531-47
Abstract: Patients with diagnosed inflammatory bowel disease (IBD) will commonly experience a clinical relapse in spite of a prolonged therapy-induced period of clinical remission. The current methods of assessing subclinical levels of low-grade inflammation which predispose patients to relapse are not optimal when considering both cost and patient comfort. Over the past few decades, much investigation has discovered that proteins such as calprotectin that are released from inflammatory cells are capable of indicating disease activity. Along with C-reactive protein and erythrocyte sedimentation rate, calprotectin has now become part of the current methodology for assessing IBD activity. More recently, research has identified that other fecal and serum biomarkers such as lactoferrin, S100A12, GM-CSF autoantibodies, α1-antitrypsin, eosinophil-derived proteins, and cytokine concentrations have variable degrees of utility in monitoring gastrointestinal tract inflammation. In order to provide direction toward novel methods of predicting relapse in IBD, we provide an up-to-date review of these biomarkers and their potential utility in the prediction of clinical relapse, given their observed activities during various stages of clinical remission.
DOI: 10.1007/s00535-016-1191-3
ORCID: 0000-0003-4219-5283
PubMed URL: 26975751
Type: Journal Article
Subjects: C-reactive protein
Appears in Collections:Journal articles

Show full item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.